A bibliometric analysis of bladder cancer and microRNA research: Trends and advances from 2008 to 2022
Wei Zhang,Gaowei Guo,Xinji Li,Jinming Lin,Zexian Zheng,Peidong Huang,Chuqi Lin,Yurong Lin,Xiaosheng Chen,Kuncheng Lin,Changzheng Zheng,Huirong Lin,Yong Lu,Hui Zhang
DOI: https://doi.org/10.1097/md.0000000000040289
IF: 1.6
2024-10-30
Medicine
Abstract:The malignant tumor is considered to be one of the most life-threatening diseases globally. Among them, bladder cancer (BC) ranks among the top 10 most prevalent malignancies globally, with an estimated 573,000 new cases and 213,000 fatalities, according to the GLOBOCAN 2020 produced by the International Agency for Research on Cancer. [ 1 ] Statistically, the chances of men developing BC at some point in their lifetime is 1.1%, whereas it is 0.27% for women. Those with carcinogen exposure, such as smoking cigarettes, have a greater likelihood of having BC. [ 2 ] BC is a carcinoma of the urothelial system, which has traditionally been referred to as transitional cell cancer. Typically, BCs are classified according to the extent of their invasion of the detrusor muscle as either non-muscle-invasive bladder cancer (NMIBC), such as Tis, Ta, and T1, or muscle-invasive bladder cancer, including T2, T3, and T4. [ 3 ] Among them, NMIBC contributes to nearly 75% of all BC diagnoses, with a 5-year recurrence and progression probability of 78% and 45%, respectively. [ 4 ] The outcomes of patients with BC largely vary according to the stage of the disease. The 5-year relative survival rate is 77% when all stages were combined. For those diagnosed with stage I disease, the 5-year relative survival rate is 80%, whereas for those diagnosed with stage IV disease, the survival rate is 14%. [ 5 ] Generally, a large number of patients with NMIBC are treated using transurethral resection of the bladder cancer, which can be successfully treated with intravesical chemotherapy or biological treatment with Bacille Calmette–Guerin. [ 6 ] Even though transurethral resection of the bladder cancer is a potentially curative option, the recurrence rate of NMIBC remains high at 1- and 5-years post-surgery, ranging from 15–61% to 31–78%, which causes serious social economic load. [ 7 ] Therefore, the decision to focus on the study of BC enables a deeper understanding and more effective management of this prevalent and intricate tumor type, ultimately leading to enhanced patient outcomes and improved quality of life.
medicine, general & internal